Milnubes / Curiosity, with sourcesBotany · Culture · Science
milnubes.
Milnubes/Encyclopedia/CBDH
Cannabinoid atlas / Reference entry
CBDH
Plant cannabinoids

Cannabidihexol

CBDH offers a useful introduction to the work of identifying similar molecules. Its interest begins before any possible application: understanding which analytical signal belongs to which structure, and how much can actually be claimed from that identification.

Documentary review: Milnubes editorial desk · assisted by AI
Close view of a microscope eyepiece with an illuminated sample.
Stock photograph providing context for this entry. It does not document a trial, participant, identified product or CBDH result.
Evidence map

Laboratory or animals. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.

How we read studies and personal accounts ↗

Identity

A CBD homologue with a six-carbon side chain, identified in 2020. It should not be confused with CBDM, a different isomer.

Source · Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol

Terms associated with this entry: cannabidihexol, CBD-C6.

A biological lead, still in animals

CBDH showed antinociceptive activity in mice; this establishes neither patient pain relief nor safety equivalent to CBD.

Source · Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol

“Tentative identification” means something

A leaf analysis published in 2026 tentatively assigned signals to CBDH and other molecules. For CBDH, that assignment did not have the same reference-standard confirmation as some other compounds in the paper.

Keeping that word prevents certainty from being inflated. Imagine a file with one folder for confirmed identifications and another for plausible candidates: both are useful for research, but they should not carry the same stamp. The distinction lets us follow research without calling every interesting signal a definitive discovery.

Source · Exploring the chemical space around Cannabis sativa L. leaves as a source of bioactive compounds of pharmaceutical interest

What has been studied

No established clinical benefit

An animal antinociceptive signal does not confirm a human treatment.

Source · Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol

Risks and gaps

Tentative identification in leaves provides no clinical safety information.

Source · Exploring the chemical space around Cannabis sativa L. leaves as a source of bioactive compounds of pharmaceutical interest

Documented forms

Signal in analysed extractsTentative leaf assignment; not a clinical product.
Source · Exploring the chemical space around Cannabis sativa L. leaves as a source of bioactive compounds of pharmaceutical interest

A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.

Experiences

We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.

Conclusion

For CBDH, a short, precise profile is more useful than a borrowed list of CBD benefits. A similar name does not supply missing evidence.

Legal context

Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.

Sources

  1. Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol · Original research
  2. Exploring the chemical space around Cannabis sativa L. leaves as a source of bioactive compounds of pharmaceutical interest · Laboratory study

Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.